Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1915282 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL1915606 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL1915279 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL1916161 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL1916166 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL17242095 | 1.00 | MME (0.43) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL17242314 | 0.88 | HTT (0.40) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL17242313 | 0.88 | HTT (0.40) | MMEHTTL3MBTL1CTSSCTSK | |
| SCHEMBL14085549 | 0.86 | CTSS (0.40) | L3MBTL1CTSSCTSK | |
| SCHEMBL7071313 | 0.82 | HKDC1 (0.39) | MMECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| EP-1060161-B1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA AS WITH SECONDARY N (DK) | 2003-06-11 | — | — | EP | disclosed |
| US-6277876-B1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2001-08-21 | — | — | US | disclosed |
| EP-1060161-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999044989-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | MME 281/4885HTT 548/4885L3MBTL1 2963/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MME 281/4885HTT 548/4885L3MBTL1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.